Cargando…
Sustained onabotulinumtoxinA therapeutic benefits in patients with chronic migraine over 3 years of treatment
BACKGROUND: Evidence on whether the therapeutic effect and good safety profile of onabotulinumtoxinA (Botox®) in chronic migraine (CM) patients is maintained over long term treatment is still limited. We herein aimed at assessing whether there is a sustained benefit and good safety with repeated ona...
Autores principales: | Vikelis, Michail, Argyriou, Andreas A., Dermitzakis, Emmanouil V., Spingos, Konstantinos C., Makris, Nikolaos, Kararizou, Evangelia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Milan
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6755578/ https://www.ncbi.nlm.nih.gov/pubmed/30225735 http://dx.doi.org/10.1186/s10194-018-0918-3 |
Ejemplares similares
-
OnabotulinumtoxinA Add-On to Monoclonal Anti-CGRP Antibodies in Treatment-Refractory Chronic Migraine
por: Argyriou, Andreas A., et al.
Publicado: (2022) -
Onabotulinumtoxin-A treatment in Greek patients with chronic migraine
por: Vikelis, Michail, et al.
Publicado: (2016) -
Assessing the Significance of the Circadian Time of Administration on the Effectiveness and Tolerability of OnabotulinumtoxinA for Chronic Migraine Prophylaxis
por: Dermitzakis, Emmanouil V., et al.
Publicado: (2022) -
Prospective Comparison of Longer Needle Lengths to Assess the Risk of OnabotulinumtoxinA-Associated Neck Pain in Patients with Chronic Migraine
por: Dermitzakis, Emmanouil V., et al.
Publicado: (2022) -
Open Label Prospective Experience of Supplementation with a Fixed Combination of Magnesium, Vitamin B2, Feverfew, Andrographis Paniculata and Coenzyme Q10 for Episodic Migraine Prophylaxis
por: Vikelis, Michail, et al.
Publicado: (2020)